DBV Technologies Stock to Reverse Split on Monday, June 3rd (NASDAQ:DBVT)

DBV Technologies S.A. (NASDAQ:DBVT) shares are set to reverse split on the morning of Monday, June 3rd. The 1-2 reverse split was announced on Monday, June 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 3rd.

DBV Technologies Price Performance

Shares of DBVT opened at $0.61 on Friday. The business’s 50-day moving average price is $0.69 and its 200-day moving average price is $0.80. DBV Technologies has a twelve month low of $0.42 and a twelve month high of $2.26. The stock has a market cap of $117.57 million, a PE ratio of -1.45 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.08. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. The firm had revenue of $1.41 million for the quarter, compared to analysts’ expectations of $3.20 million. Analysts expect that DBV Technologies will post -0.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. StockNews.com assumed coverage on DBV Technologies in a report on Wednesday. They set a “hold” rating for the company. HC Wainwright cut their price objective on DBV Technologies from $10.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, May 8th.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Landscape Capital Management L.L.C. purchased a new stake in shares of DBV Technologies during the third quarter valued at approximately $94,000. Cowen AND Company LLC purchased a new stake in shares of DBV Technologies during the fourth quarter valued at approximately $49,000. Optiver Holding B.V. boosted its stake in shares of DBV Technologies by 595.2% during the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after purchasing an additional 235,337 shares during the period. Finally, Yiheng Capital Management L.P. raised its holdings in shares of DBV Technologies by 6.2% during the first quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock valued at $4,172,000 after acquiring an additional 327,345 shares in the last quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.